Vitamin D is unusual because it has actually been tested at scale, which means we know a great deal about what it does not do. VITAL, with over 25,000 participants, found no reduction in invasive cancer incidence or cardiovascular events. A 2018 Lancet Diabetes & Endocrinology meta-analysis concluded supplementation does not prevent fractures or falls or meaningfully change bone mineral density, and found no difference between higher and lower doses. DO-HEALTH found no significant effect on blood pressure, non-vertebral fractures, physical performance, infection rates or cognition. The benefit that survives is concentrated in people who were low to begin with.
Vitamin D3 (cholecalciferol) is a fat-soluble secosteroid that the skin synthesizes on exposure to ultraviolet-B light and that is also obtained from foods and supplements. It is converted in the liver to 25-hydroxyvitamin D (calcidiol), the main circulating marker of vitamin D status, and then to the active hormone calcitriol, which regulates calcium and phosphate homeostasis and bone metabolism and has broad effects on immune function. Because vitamin D3 is highly hydrophobic, its oral absorption depends on accompanying lipids; liposomal (phospholipid-encapsulated) formulations are marketed to improve bioavailability, and a small clinical study reported that a liposomal preparation raised blood calcidiol more rapidly than an oil-based formulation.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“Supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo.”
“Our findings suggest that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density. There were no differences between the effects of higher and lower doses of vitamin D.”
“Among adults without major comorbidities aged 70 years or older, treatment with vitamin D3, omega-3s, or a strength-training exercise program did not result in statistically significant differences in improvement in systolic or diastolic blood pressure, nonvertebral fractures, physical performance, infection rates, or cognitive function.”
“However, there were no differences in change in leg power, leg or grip strength, SPPB score, TUG, postural sway, or gait velocity and spatiotemporal parameters by intervention group over 12 mo or muscle fiber composition and contractile properties over 4 mo.”
“vitamin D administered daily reduced cancer mortality by 12 percent”
Result: The main meta-analysis of 14 RCTs showed a non-significant 6% reduction in cancer mortality (RR: 0.94 [0.86-1.02]). Subgroup analysis revealed a 12% lower cancer mortality in trials with a daily dosing regimen (RR: 0.88 [0.78-0.98]), but no reduction in trials using a bolus regimen (RR: 1.07 [0.91-1.24]). The IPD meta-analysis confirmed…
Stated limitations: The study noted insufficient data on baseline 25-hydroxyvitamin D levels and limited inclusion of non-Hispanic White adults in the trials, which prevented drawing conclusions for these subgroups.
Large randomized trials and meta-analyses give a mixed picture. In generally healthy, vitamin-D-replete adults the two biggest trials were null on their primary endpoints: VITAL (25,871 people, 2,000 IU/day for a median 5.3 years) did not reduce invasive cancer, major cardiovascular events or death, and DO-HEALTH found no benefit for fractures, physical function or cognition in adults over 70. Secondary analyses, however, produced genuinely interesting signals: about 12% lower cancer mortality with daily (not bolus) dosing in an individual-patient meta-analysis, a 22% lower rate of autoimmune disease in VITAL, fewer acute respiratory infections (greatest in deficient people), and — in a 2025 VITAL substudy — preserved leukocyte telomere length over four years, the first large randomized signal on a biological-aging marker. These are ancillary findings that need replication, not reasons for high-dose use. Benefits are clearest in people who begin with low vitamin D status, pointing toward correcting deficiency rather than universal supplementation. This evidence describes vitamin D3 (cholecalciferol) and its measured blood levels rather than this specific commercial liposomal product.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
Test your 25(OH)D before you buy anything. If you are low, daily dosing at conventional amounts is cheap, well studied and sensible, and the benefit signal in the trials is concentrated exactly there. If you are already in range, the largest randomized trials in the field say you are unlikely to get anything for your money, and there is no dose-escalation evidence that rewards taking more.
Graded Strong. If the goal is cardiovascular risk, this measures something vitamin D did not move in VITAL or DO-HEALTH.
Graded Strong for falls and mobility — the endpoint vitamin D failed on in the Lancet meta-analysis.
Graded Strong for muscle and exercise performance, which is the outcome the vitamin D strength trial could not find.
Graded Strong. An example of what a supplement looks like when the trials line up behind a specific, measurable claim.
Vitamin D molecule page · Bone density · Telomeres · Mail-in blood panels: what a drop of blood can and cannot measure · The BMJ mortality meta-analysis, in full · The graded supplement guide
Sibling pages in this record: NMN (nicotinamide mononucleotide) · Resveratrol · Omega-3 fish oil · Blue-light filtering glasses
Open Dr. Mercola Liposomal Vitamin D3 in the Magellan store →
That is a question for your clinician and for your 25(OH)D result, not for a web page. What the evidence supports is this: correcting a genuine deficiency is worth doing, daily dosing beats large intermittent boluses in the infection literature, and in people who are already replete the biggest randomized trials found no benefit for cancer incidence, cardiovascular events, fractures or falls.
Because low vitamin D is an excellent marker of being unwell, indoors, inactive or older — all of which independently predict bad outcomes. Randomization breaks that link, which is why VITAL and DO-HEALTH read so differently from the cohort literature. This pattern repeats across the supplement world.
In a VITAL substudy of about 1,000 adults, 2,000 IU/day slowed leukocyte telomere shortening over four years — roughly 140 base pairs preserved. It is the first large randomized signal on a biological-aging marker, and it comes from an ancillary analysis. We report it and we flag it as needing replication, because a marker is not an outcome.
There is no trial showing that it is. Vitamin D is fat-soluble and absorbs well with a meal, so the problem liposomal delivery solves is not obviously a problem vitamin D has. We list it and we say this on the product page.